Researchers have updated the American Urological Association (AUA) guidelines to strengthen the recommendation for Aquablation therapy, a robotic treatment for men suffering from lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). This therapy is now recommended for men with prostate sizes ranging from 30 to 150 mL, which means more men can benefit from this innovative treatment.

For those looking to age well, this update is significant. Aquablation therapy has been shown to provide long-lasting improvements in urinary symptoms and flow rates for men with BPH, a condition that affects around 40 million men in the United States. If you or someone you know is experiencing urinary issues related to an enlarged prostate, this therapy could lead to better urinary health and improved quality of life.

The evidence supporting Aquablation therapy comes from randomized clinical trials that demonstrate its effectiveness over other surgical options, such as traditional transurethral resection of the prostate (TURP) and laser enucleation. These studies show durable outcomes for men with varying prostate sizes, making this treatment a viable option for a broader range of patients. As the clinical evidence matures, healthcare providers are increasingly adopting Aquablation therapy in practice.

If you are considering options for managing BPH, discussing Aquablation therapy with your healthcare provider could be beneficial. It’s essential to weigh the potential benefits against any associated risks, as with any surgical treatment. Always consult with a medical professional to determine the best course of action for your specific health needs.

Source: globenewswire.com